You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Takeda’s Exkivity receives MHRA conditional marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Exkivity (mobocertinib), as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) locally advanced or metastatic non-small cell lung cancer.